Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence
about
Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulantsOptimizing the treatment of mood disorders in the perinatal periodPerinatal vs genetic programming of serotonin states associated with anxiety.Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function.Antidepressant medication during pregnancy and epigenetic changes in umbilical cord blood: a systematic reviewSerotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal developmentAntidepressants may mitigate the effects of prenatal maternal anxiety on infant auditory sensory gating.Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors: Implications for Sex Differences, Early Stress and Prenatal SSRI ExposureDopamine and serotonin signaling during two sensitive developmental periods differentially impact adult aggressive and affective behaviors in mice.Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetineEarly-life serotonin dysregulation affects the migration and positioning of cortical interneuron subtypes.NEUROBIOLOGICAL PREDICTORS OF RESPONSE TO DORSOLATERAL PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN DEPRESSION: A SYSTEMATIC REVIEW.Returning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges.Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescenceFetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brainNeonatal pharmacology: rational therapeutics for the most vulnerablePostnatal day 2 to 11 constitutes a 5-HT-sensitive period impacting adult mPFC function.New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum.Psychoactive pharmaceuticals induce fish gene expression profiles associated with human idiopathic autismDevelopmental exposure to fluoxetine modulates the serotonin system in hypothalamus.Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.A transient placental source of serotonin for the fetal forebrainSerotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxietyOlanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens.Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.The serotonergic anatomy of the developing human medulla oblongata: implications for pediatric disorders of homeostasisMaternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: implications for fetal programmingPlacental source for 5-HT that tunes fetal brain development.The effects of depression and use of antidepressive medicines during pregnancy on the methylation status of the IGF2 imprinted control regions in the offspring.Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats.Neonatal SSRI Exposure Programs a Hypermetabolic State in Adult Mice.The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism.Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark.Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception.Disruption of 5-HT1A function in adolescence but not early adulthood leads to sustained increases of anxietyRethinking 5-HT1A receptors: emerging modes of inhibitory feedback of relevance to emotion-related behaviorThe Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month.Placental serotonin: implications for the developmental effects of SSRIs and maternal depressionFluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats.
P2860
Q22251215-FAA731A2-89F1-447C-9509-7906294A3566Q26798225-46B334E2-EEA5-4E35-86F8-250E42B69517Q27311047-C79A67F8-4C7B-4282-BB9B-907A564747B3Q27313333-B1192C29-7335-42E6-B898-367BC5674795Q28075452-E3B5AC05-28FC-43A1-A720-0305BBFE1FC9Q28741999-1674CAC5-75C0-4BE6-B0A6-653340558DCCQ30453943-E6A066EC-C639-45D0-A7A4-0584005CC1A9Q30469931-EE82370E-4837-4076-A1B9-CAF4EA9E0A71Q30619328-59A3149E-D968-46D7-BE27-95B0ABB6D496Q30762930-B336F734-9268-4FF8-85A3-B8DAB9827C82Q30823860-427D8866-2F08-498E-96ED-5B779FC25F1DQ30994290-E22FCCCA-58D0-4B6A-A41B-CDF465654FCDQ33976001-717D5773-C4CD-4C18-8AF1-58189A6B836FQ34017808-6EED0B84-85ED-4243-9D2E-B2AA4399E9A7Q34029017-6F802104-E8FA-44EE-8140-AB7217693E30Q34088196-6695C713-6DF8-4266-9474-4B9E322A058EQ34162744-A951C429-7811-4CDE-A4FE-3AE7E3E1B6BDQ34177689-E46BC01F-CE06-445C-94F9-F192A5ED8FBBQ34305076-1FAAD3B2-002C-4BF8-ADF8-A8CD5A10C45AQ34576006-96FE0135-5D2E-4E0B-A92C-13A7001F7CFEQ34620074-AE9D8B32-C0E9-4C67-A9EE-6F5ABBC932FEQ34714284-0DD1231F-263A-48B6-8B5B-75A9DE1F75B4Q34881930-D0748118-742C-4606-9226-E74787C0BE06Q35008700-A3536340-A291-4F98-8F34-C3C835FC5CB7Q35021488-E298C005-7919-4A9D-8528-172F41E2548EQ35090255-247AC119-85E0-4FAF-A1F1-AF91AC73FDD4Q35098779-AC752CE2-AB1F-454A-B143-077ED39B51B3Q35161157-FC362496-9A32-4CAA-A393-892FEB137832Q35614116-AB385ECA-34A6-49F4-BFC2-6D0553BAD7FCQ35670663-217318F4-B853-4CFD-8638-B7823FDC373CQ35853507-FC6017AF-5903-4F86-9159-4C222BC09045Q35909234-7B2B6162-234E-4494-9620-C30A47EDF26FQ36035922-AE65B20A-D9B7-4C98-88A2-3E35EAA14E36Q36209588-2342F2AC-1740-4605-8786-663F34ACD1A9Q36336176-B70E434F-16C1-41B6-A95B-7E831D1CF3AAQ36345622-27B3DB8D-FF75-43E2-840F-0DBB8ED91140Q36540897-724CFF6A-F820-4D90-A4B5-382CD220DF8AQ36547279-6ACC89AE-A58A-4B80-9684-815C1F872C16Q36785491-E164C533-8B0D-4158-8463-A1F7C3B40334Q36806023-EC81028D-DB64-45E8-967F-F93F512A3284
P2860
Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Sustained neurobehavioral effe ...... molecular to clinical evidence
@en
Sustained neurobehavioral effe ...... olecular to clinical evidence.
@nl
type
label
Sustained neurobehavioral effe ...... molecular to clinical evidence
@en
Sustained neurobehavioral effe ...... olecular to clinical evidence.
@nl
prefLabel
Sustained neurobehavioral effe ...... molecular to clinical evidence
@en
Sustained neurobehavioral effe ...... olecular to clinical evidence.
@nl
P2093
P2860
P356
P1476
Sustained neurobehavioral effe ...... molecular to clinical evidence
@en
P2093
J A Gingrich
M S Ansorge
T F Oberlander
P2860
P304
P356
10.1038/CLPT.2009.201
P407
P577
2009-11-04T00:00:00Z